Compare DBI & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBI | CDXS |
|---|---|---|
| Founded | 1991 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.2M | 256.3M |
| IPO Year | 2005 | 2008 |
| Metric | DBI | CDXS |
|---|---|---|
| Price | $6.23 | $1.49 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.75 | N/A |
| AVG Volume (30 Days) | 519.1K | ★ 1.3M |
| Earning Date | 06-09-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | 15.00 | ★ 43.82 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $2,892,671,000.00 | $138,590,000.00 |
| Revenue This Year | $1.29 | $7.73 |
| Revenue Next Year | $1.88 | $14.24 |
| P/E Ratio | $320.00 | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $2.55 | $0.96 |
| 52 Week High | $9.17 | $3.87 |
| Indicator | DBI | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 25.53 |
| Support Level | $5.96 | $1.04 |
| Resistance Level | $8.28 | $1.86 |
| Average True Range (ATR) | 0.32 | 0.14 |
| MACD | 0.12 | -0.09 |
| Stochastic Oscillator | 72.06 | 3.10 |
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in two reportable segments: the Retail segment and the Brand Portfolio segment. The Retail segment, which derives key revenue, operates the DSW Designer Shoe Warehouse ("DSW") banner through its direct-to-consumer stores and e-commerce sites in the United States ("U.S.") and Canada, and the Shoe Co. and Rubino banners through its direct-to-consumer stores and e-commerce sites in Canada. The Brand Portfolio segment principally earns revenue from the wholesale of its exclusive and licensed brands to retailers, its Retail segment, and international distributors, and the sale of its Vince Camuto, Keds, and Topo brands through direct-to-consumer e-commerce sites.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.